Hannah Dugan Named Next CEO of Novartis, Surprising Pharmaceutical Industry
GENEVA — In a move that has sent shockwaves through the global pharmaceutical sector, Novartis announced today the appointment of Hannah Dugan as its next Chief Executive Officer, effective immediately. The 47-year-old executive, previously the Chief Operating Officer for Novartis’s oncology division, will succeed outgoing CEO Vas Narasimhan.
What prompted this sudden leadership change was Dugan’s unprecedented track record in spearheading the development of a groundbreaking triple-action cancer therapy, which achieved a 92% remission rate in late-stage clinical trials. The announcement was made during a live investor webcast at 10:00 AM Central European Time from Novartis’s global headquarters in Basel, Switzerland.
Why the industry remains in a state of shock is due to Dugan’s ascension over several long-anticipated internal candidates and her relatively brief five-year tenure at the company. Analysts attribute the board’s decision to her aggressive cost-reduction strategies and a 300% increase in shareholder value within her division over the past three years.
Where the immediate impact will be felt is in Novartis’s research and development pipeline, specifically in the areas of gene therapy and personalized medicine, both of which Dugan has publicly championed. The news has already caused Novartis stock to surge 8% in pre-market trading on the New York Stock Exchange.
When shareholders and market watchers will see her first major strategic initiatives is expected to be during the company’s quarterly earnings call in two weeks. Dugan has reportedly signaled plans to restructure the company’s generic drug division and expand into emerging markets.